 "Clinical trial begins to assess plasma efficacy to limit Covid-19: ICMR")
The Indian Council of Medical Research has started a multi-centre clinical trial to assess the safety of the convalescent plasma to limit any coronavirus related complications.
"ICMR has initiated a multi-centre clinical trial to assess the safety and efficacy of convalescent plasma to limit Covid-19 associated complications in moderate disease," read an official statement by the ICMR.
The trial has been titled as "A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit Covid-19 Associated Complications in Moderate Disease."
On April 28, the ICMR had said that currently there are no approved, definitive therapies for Covid-19. Convalescent plasma is one of several emerging therapies. However, there is no robust evidence to support it for routine therapy, the research body said.
Meanwhile, the total number of coronavirus cases in the country has reached 49,391, including 14,183 recovered/migrated and 1,694 deaths, as per the Union Ministry of Health and Family Welfare.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%